$NBIO - Once successfully commercialized, the Company hopes to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits. https://finance.yahoo.com/news/nascent-collaborates-hypospray-pharma-proprietary-120000958.html